Rybelsus
Indicated to manage type 2 diabetes and developed to support blood sugar control and alleviate weight-related health risks in patients.
Strengths: 3 · 7 · 14mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Ozempic; Wegovy
- Therapeutic class
Glucagon-like Peptide-1 (GLP-1) Receptor Agonist
- Pharmacological class
GLP-1 Receptor Agonist
- Known off-label uses
obesity
- Precautions and warnings
maintain adequate hydration; monitor blood sugar levels
- Minor side effects
nausea; diarrhoea
- Moderate side effects
vomiting; abdominal pain; constipation
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Novo Nordisk
- Onset Time
weeks
- Duration
long term
- Storage instructions
Store in original card in a dry place.
- Drug interactions
insulin; sulphonylureas
- Age restrictions
18 years and older.
- Pregnancy and breastfeeding
Not recommended during pregnancy.
Contraindications
medullary thyroid carcinoma history; multiple endocrine neoplasia syndrome type 2
Serious side effects
pancreatitis — requires immediate medical attention; gallbladder disease — requires immediate medical attention
Patient summary
Indicated to manage type 2 diabetes and developed to support blood sugar control and alleviate weight-related health risks in patients.
Mechanism of action
Semaglutide is a GLP-1 receptor agonist that mimics the body's natural incretin hormone. It enhances insulin secretion, suppresses glucagon levels, and slows gastric emptying, which helps to lower blood glucose concentrations and promote satiety.
Rybelsus
Indicated to manage type 2 diabetes and developed to support blood sugar control and alleviate weight-related health risks in patients.
Editorial Notes
- Active ingredient(s): Semaglutide
- Listed indication(s): Type 2 Diabetes Mellitus
Usually available as
- 10 tablets - 3 mg998-3-mg-12607
- 10 tablets - 7 mg998-7-mg-12608
- 10 tablets - 14 mg998-14-mg-12609